
launch long-term recoveri
maintain neutral rate teva share think
manag abil rais financi target challeng
environ encourag copaxon austedo sale continu
exceed estim increas ep estim
top end co ep guidanc believ
key focu remain success launch ajovi prevent
migrain market crowd rate
novarti nv rate aimovig lead eli lilli
rate emgal also compet market share think ajovi once-
quarterli dose profil sourc differenti vs other
dose per month still earli launch alreadi
ajovi volum come quarterli dose
teva still face challeng oper environ within
gener brand segment result came better
expect driven anoth quarter higher expect
copaxon sale american sale vs estimate
contribut adj gross profit margin basi point
higher forecast teva report revenu vs
estimate adj ep vs estimate co benefit
lower oper expens vs estimate
much lower expect tax rate vs estimate
updat guidanc manag increas adj ebitda
target ep
 free cash flow
up ep estimate upper end co
guidanc rang ebitda estimate
valuat maintain neutral rate teva share
believ manag execut lower cost structur
benefit higher expect copaxon sale teva net debt
stand assign pt neutral-r stock
dcf analysi suggest teva share worth
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
teva quarterli result benefit higher copaxon sale combin lower
cost associ on-going restructur effort
maintain neutral rate teva share think manag abil rais financi target
challeng environ encourag increas ep estim top end
co ep guidanc believ key focu remain success launch ajovi
prevent migrain market crowd rate novarti nv
rate aimovig lead eli lilli rate emgal also compet market share think
ajovi once-quarterli dose profil sourc differenti vs other dose per month
still earli launch alreadi ajovi volum come quarterli dose
teva still face challeng oper environ within gener brand segment result
came better expect driven anoth quarter higher expect copaxon sale american
sale vs estimate contribut adj gross profit margin basi point higher
forecast teva report revenu vs estimate adj ep vs
estimate co benefit lower oper expens vs estimate much lower
expect tax rate vs estimate
teva report revenu vs estimate adjust ep vs estimate
solid execut manag lead upward guidanc revis up
ep estim
guidanc increas primarili driven result higher copaxon sale tighter expens control
benefit lower tax rate ep estim upper end co guidanc
rang ebitda estimate
manag increas adj ebitda target ep
 free cash flow
wouldnt surpris see higher copaxon sale occur think gener version mylan
buy pt sandoz nv rate like greater impact start insur
potenti look lower cost push patient switch gener copaxon treatment relapsing-
remit ms quarterli sale remain steadi global sale ratchet
american copaxon sale forecast quarter estim
teva continu benefit sale copaxon expect price volum eros acceler
global copaxon revenu quarter
 novarti aimovig migrain headach lead teva ajovi lilli
teva ajovi recent gain approv prevent episod chronic migrain eli
lilli emgal galcenezumab follow suit three approv cgrp antagonist drug prevent
migrain headach would expect market battl begin drug co plot strategi
gain share new patient gener meaning sale road view
rate novarti nv rate benefit first product gain fda approv may sinc
introduct may aimovig prescript volum ramp new total prescript
dispens septemb accord symphoni health teva call co highlight negoti
number major payor expect gross-to-net discount rang
howev think figur could increas competitor may offer even greater discount
estim ajovi sale sale sale excess
aimovig leader cgrp pack current weekli volum
ajovi efficaci seem compar cgrp-antagonist high incid inject site
reaction issu current think aimovig advantag first product gain approv
addit side effect profil notic incid inject site reaction aimovig
vs ajovi incid contrast lilli emgal show inject site reaction rate
addit believ teva auto injector version ajovi avail launch could put
disadvantag peer
efficaci ajovi compar aimovig prevent episod chronic migrain
compar product label teva ajovi novarti aimovig cgrp antagonist
demonstr stat signific reduct monthli migrain day mmd day vs placebo
product show similar percentag patient achiev greater equal reduct baselin
mean monthli migrain day period time ajovi patient dose
per month respond patient dose per quarter respond
aimovig patient dose per month achiev respons rate higher
per month dose show respons rate evalu month
ajovi sourc differenti once-quarterli dose profil could
advantag vs aimovig emgal are dose per month
clinic studi ajovi show averag reduct headach day per month patient
suffer chronic migrain studi nct includ adult histori chronic migrain
patient headach day per month patient random receiv subcutan
inject either ajovi mg start dose follow mg monthli mg everi month quarterli
placebo monthli treatment period patient allow use acut headach treatment
studi subset patient allow use one addit concomit prevent medic
studi exclud patient histori signific cardiovascular diseas vascular ischemia thrombot
event cerebrovascular accid transient ischem attack deep vein thrombosi pulmonari
primari efficaci endpoint mean chang baselin monthli averag number headach
day least moder sever treatment period secondari endpoint mean
chang baselin monthli averag number migrain day treatment period
proport patient reach least reduct monthli averag number headach day least
moder sever treatment period mean chang baselin monthli averag
number day use acut headach medic treatment period mean
chang baselin number headach day least moder sever first month
ajovi studi result show patient take ajovi dose per month per
quarter experienc stat signific reduct number headach day per month
teva pharmaceut industri ltd teva earn model gross oper expens pre-tax adj incom net average share adj analysistot earn per compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
